Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Advanz Pharma
Pharma
Intercept's Ocaliva nod in danger after negative FDA adcomm vote
With a negative FDA advisory committee vote, the future of Intercept’s rare liver disease drug Ocaliva is under serious threat.
Fraiser Kansteiner
Sep 16, 2024 10:40am
Ocaliva's fate looks bleak after FDA releases new briefing docs
Sep 11, 2024 4:58pm
In appeal, Advanz calls UK fine 'manifestly wrong'
Sep 27, 2022 3:48pm
Advanz bags EU rights to Polypid's prolonged-release antibiotic
Aug 9, 2022 9:54am
Intercept sells international rights to Ocaliva to Advanz
May 5, 2022 11:05am
The UK dished out a second drug pricing fine this month
Jul 30, 2021 10:45am
